Phosphodiesterase inhibitors in airways disease

European Journal of Pharmacology

Volumn 533, Issue 1-3, 2006, Pages 110-117

  Fan Chung, Kian ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Cilomilast; Phosphodiesterase; Phosphodiesterase inhibitor; Roflumilast; Rolipram

Indexed keywords

2 [4 [6,7 DIETHOXY 2,3 BIS(HYDROXYMETHYL) 1 NAPHTHYL] 2 PYRIDYL] 4 (3 PYRIDYL) 1(2H) PHTHALAZINONE; 3 (3 CYCLOPENTYLOXY 4 METHOXYBENZYL) 6 ETHYLAMINO 8 ISOPROPYL 3H PURINE; 4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; 6 (4 ACETAMIDOPHENYL) 1,2,3,4,4A,10B HEXAHYDRO 8,9 DIMETHOXY 2 METHYLBENZO[C][1,6]NAPHTHYRIDINE; 7 METHOXYBENZOFURAN 4 CARBOXAMIDE DERIVATIVE; BAY 198004; BECLOMETASONE; C 3885; CC 7075; CC 7085; CI 1044; CILOMILAST; ISOPRENALINE; KW 4490; MOTAPIZONE; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PHOSPHODIESTERASE VII INHIBITOR; PHTALAZINE DERIVATIVE; PICLAMILAST; ROFLUMILAST; ROLIPRAM; SIGUAZODAN; SILDENAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAPRINAST; ZARDAVERINE;

ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYTOKINE RELEASE; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; EMPHYSEMA; EOSINOPHIL; EXERCISE INDUCED ASTHMA; FIBROSIS; HUMAN; HYDROLYSIS; IMMUNE RESPONSE; INFLAMMATORY CELL; MACROPHAGE; NAUSEA; NAUSEA AND VOMITING; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; RHINOPHARYNGITIS; SMOOTH MUSCLE RELAXATION; T LYMPHOCYTE ACTIVATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMINOPYRIDINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BENZAMIDES; CARBOXYLIC ACIDS; CLINICAL TRIALS; CYCLOPROPANES; HUMANS; ISOENZYMES; NITRILES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33644811309     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.12.059     Document Type: Review

References (81)

1. A. Albrecht, S. Leichtl, D. Bredenbroker, T.D. Bethke, and W. Wurst A new orally active, selective phosphodiesterase inhibitor, with beclomethasone propionate in asthma control Eur. Respir. J. 20 suppl 38 2002 304S
2. M. Ariga, B. Neitzert, S. Nakae, G. Mottin, C. Bertrand, M.P. Pruniaux, S.L. Jin, and M. Conti Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation J. Immunol. 173 2004 7531 7538
3. R. Barber, G.S. Baillie, R. Bergmann, M.C. Shepherd, R. Sepper, M.D. Houslay, and G.V. Heeke Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers Am. J. Physiol., Lung Cell. Mol. Physiol. 287 2004 L332 L343
4. M.S. Barnette, J.O. Bartus, M. Burman, S.B. Christensen, L.B. Cieslinski, K.M. Esser, U.S. Prabhakar, J.A. Rush, and T.J. Torphy Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding Biochem. Pharmacol. 51 1996 949 956
5. J.A. Beavo Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms Physiol. Rev. 75 1995 725 748
6. J.A. Beavo, M. Conti, and R.J. Heaslip Multiple cyclic nucleotide phosphodiesterases Mol. Pharmacol. 46 1994 399 405
7. C. Belleguic, M. Corbel, N. Germain, E. Boichot, P. Delaval, and V. Lagente Reduction of matrix metalloproteinase-9 activity by the selective phosphodiesterase 4 inhibitor, RP 73-401 in sensitized mice Eur. J. Pharmacol. 404 2000 369 373
8. T.J. Bloom, and J.A. Beavo Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants Proc. Natl. Acad. Sci. U. S. A. 93 1996 14188 14192
9. T. Brunnee, R. Engelstatter, V.W. Steinijans, and G. Kunkel Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma Eur. Respir. J. 5 1992 982 985
10. C. Burnouf, E. Auclair, N. Avenel, B. Bertin, C. Bigot, A. Calvet, K. Chan, C. Durand, V. Fasquelle, F. Feru, R. Gilbertsen, H. Jacobelli, A. Kebsi, E. Lallier, J. Maignel, B. Martin, S. Milano, M. Ouagued, Y. Pascal, M.P. Pruniaux, J. Puaud, M.N. Rocher, C. Terrasse, R. Wrigglesworth, and A.M. Doherty Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors J. Med. Chem. 43 2000 4850 4867
11. C. Burnouf, and M.P. Pruniaux Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs Curr. Pharm. Des 8 2002 1255 1296
12. A. Castro, M.J. Jerez, C. Gil, and A. Martinez Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors Med. Res. Rev. 25 2005 229 244
13. N.B. Charan Does sildenafil also improve breathing? Chest 120 2001 305 306
14. C. Compton, E. Cedar, R.B. Nieman, O. Omit, S.J. Langley, and M. Sapene Ariflo improves pulmonary function in patients with asthma: results of a study in patients taking inhaled corticosteroids Am. J. Respir. Crit. Care Med. 195 1999 A624
15. C.H. Compton, M. Duggan, and E. Cedar Ariflo efficacy in a 12 month study of patients with asthma Am. J. Respir. Crit. Care Med. 161 2000 A505
16. C.H. Compton, J.D. Eddlestone, and E. Cedar Cilomilast (Ariflo) 15 mg bid safety in a 6 month clinical trial programme Am. J. Respir. Crit. Care Med. 163 2001 A909
17. C.H. Compton, J. Gubb, R. Nieman, J. Edelson, O. Amit, A. Bakst, J.G. Ayres, J.P. Creemers, G. Schultze-Werninghaus, C. Brambilla, and N.C. Barnes Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study Lancet 358 2001 265 270
18. M. Conti, G. Nemoz, C. Sette, and E. Vicini Recent progress in understanding the hormonal regulation of phosphodiesterases Endocr. Rev. 16 1995 370 389
19. M. Corbel, N. Germain, J. Lanchou, S. Molet, P.M. Silva, M.A. Martins, E. Boichot, and V. Lagente The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor-beta release during acute lung injury in mice: the role of the balance between tumor necrosis factor-alpha and interleukin-10 J. Pharmacol. Exp. Ther. 301 2002 258 265
20. J.D Eddleston, C.H. Compton, and R. Nieman Cilomilast (ariflo) a potent selective inhibitor of phosphodiesterase 4 improves lung functions in patients with COPD: results of a six month trial Am. J. Respir. Crit. Care Med. 163 2001 A277
21. J.D. Eddleston, C.H. Compton, and R. Nieman Cilomilast (ariflo) a potent selective inhibitor of phosphodiesterase 4 inhibitor reduces exacerbations in COPD patients: results of a six month trial Am. J. Respir. Crit. Care Med. 163 2001 A771
22. S.D. Edmondson, A. Mastracchio, J. He, C.C. Chung, M.J. Forrest, S. Hofsess, E. MacIntyre, J. Metzger, N. O'Connor, K. Patel, X. Tong, M.R. Tota, L.H. Van der Ploeg, J.P. Varnerin, M.H. Fisher, M.J. Wyvratt, A.E. Weber, and E.R. Parmee Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors Bioorg. Med. Chem. Lett. 13 2003 3983 3987
23. L. Foissier, M. Lonchampt, F. Coge, and E. Canet In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor J. Pharmacol. Exp. Ther. 278 1996 1484 1490
24. R.W. Foster, and K. Rakshi Bronchodilator potency, effectiveness and time course of inhaled nebulised AH 21-132 in normal human subjects Br. J. Pharmacol. 99 1990 193P
25. E. Gamble, D.C. Grootendorst, C.E. Brightling, S. Troy, Y. Qiu, J. Zhu, D. Parker, D. Matin, S. Majumdar, A.M. Vignola, C. Kroegel, F. Morell, T.T. Hansel, S.I. Rennard, C. Compton, O. Amit, T. Tat, J. Edelson, I.D. Pavord, K.F. Rabe, N.C. Barnes, and P.K. Jeffery Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (ariflo) in chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 168 2003 976 982
26. H.A. Ghofrani, R. Voswinckel, F. Reichenberger, H. Olschewski, P. Haredza, B. Karadas, R.T. Schermuly, N. Weissmann, W. Seeger, and F. Grimminger Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study J. Am. Coll. Cardiol. 44 2004 1488 1496
27. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2 Br. J. Pharmacol. 118 1996 1945 1958
28. N.A. Glavas, C. Ostenson, J.B. Schaefer, V. Vasta, and J.A. Beavo T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3 Proc. Natl. Acad. Sci. U. S.A. 98 2001 6319 6324
29. V. Goncalves, d.M., M. Singer, B.B. Vargaftig, and M. Chignard Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide- induced inflammation in mouse lung Br. J. Pharmacol. 123 1998 631 636
30. D.E. Griswold, E.F. Webb, A.M. Badger, P.D. Gorycki, P.A. Levandoski, M.A. Barnette, M. Grous, S. Christensen, and T.J. Torphy SB 207499 (ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo J. Pharmacol. Exp. Ther. 287 1998 705 711
31. G. Hansen, S. Jin, D.T. Umetsu, and M. Conti Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D Proc. Natl. Acad. Sci. U. S. A. 97 2000 6751 6756
32. Hatzelmann, A., Marx, D., Steinhilber, W., and Altana Pharma AG., 2002. Phthalazinone derivatives useful as PDE4/7 inhibitors (WO02085906).
33. M.D. Houslay, and D.R. Adams PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization Biochem. J. 370 2003 1 18
34. Z. Huang, Y. Ducharme, D. MacDonald, and A. Robichaud The next generation of PDE4 inhibitors Curr. Opin. Chem. Biol. 5 2001 432 438
35. S.L. Jin, and M. Conti Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses Proc. Natl. Acad. Sci. U. S.A. 99 2002 7628 7633
36. T. Kohyama, X. Liu, F.Q. Wen, Y.K. Zhu, H. Wang, H.J. Kim, H. Takizawa, L.B. Cieslinski, M.S. Barnette, and S.I. Rennard PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels Am. J. Respir. Crit. Care Med. 26 2002 694 701
37. T. Kohyama, X. Liu, Y.K. Zhu, F.Q. Wen, H.J. Wang, Q. Fang, T. Kobayashi, and S.I. Rennard Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase Am. J. Respir. Crit. Care Med. 27 2002 487 494
38. R.K. Kumar, C. Herbert, P.S. Thomas, L. Wollin, R. Beume, M. Yang, D.C. Webb, and P.S. Foster Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma J. Pharmacol. Exp. Ther. 307 2003 349 355
39. H. Kuss, N. Hoefgen, S. Johanssen, T. Kronbach, and C. Rundfeldt In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4- fluorobenzyl)-5-hydroxy-indole-3-yl]-glyo xylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration J. Pharmacol. Exp. Ther. 307 2003 373 385
40. V. Lagente, I. Moodley, S. Perrin, G. Mottin, and J.L. Junien Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung Eur. J. Pharmacol. 255 1994 253 256
41. V. Lagente, M.P. Pruniaux, J.L. Junien, and I. Moodley Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors Am. J. Respir. Crit. Care Med. 151 1995 1720 1724
42. V. Lagente, C. Martin-Chouly, E. Boichot, M.A. Martins, and P.M. Silva Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases Mem. Inst. Oswaldo Cruz 100 Suppl 1 2005 131 136
43. N. Lazzeri, M.G. Belvisi, H.J. Patel, M.H. Yacoub, K.F. Chung, and J.A. Mitchell Effects of prostaglandin E2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells. Relevance to asthma therapy Am. J. Respir. Cell Mol. Biol. 24 2001 44 48
44. S. Leichtl, C. Schmid-Wirlitsch, D. Bredenbroker, F. Rathgeb, and W. Wurst Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor is effective in the treatment of asthma Eur. Respir. J. 20 Suppl 38 2002 303S
45. L. Li, C. Yee, and J.A. Beavo CD3- and CD28-dependent induction of PDE7 required for T cell activation Science 283 1999 848 851
46. C.A. Martin-Chouly, A. Astier, C. Jacob, M.P. Pruniaux, C. Bertrand, and V. Lagente Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors Life Sci. 75 2004 823 840
47. P.A. Martorana, R. Beume, M. Lucattelli, L. Wollin, and G. Lungarella Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke Am. J. Respir. Crit. Care Med. 172 2005 848 853
48. M. Mata, B. Sarria, A. Buenestado, J. Cortijo, M. Cerda, and E.J. Morcillo Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells Thorax 60 2005 144 152
49. E. Meacci, M. Taira, M. Moos Jr., C.J. Smith, M.A. Movsesian, E. Degerman, P. Belfrage, and V. Manganiello Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase Proc. Natl. Acad. Sci. U. S. A. 89 1992 3721 3725
50. X. Miro, S. Perez-Torres, J.M. Palacios, P. Puigdomenech, and G. Mengod Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs Synapse 40 2001 201 214
51. K. Nakata, K.S. Akagawa, M. Fukayama, Y. Hayashi, M. Kadokura, and T. Tokunaga Granulocyte-macrophage colony-stimulating factor promotes the proliferation of human alveolar macrophages in vitro J. Immunol. 147 1991 1266 1272
52. J.L. Ortiz, J.M. Valles, M. Marti-Cabrera, J. Cortijo, and E.J. Morcillo Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs Naunyn-Schmiedeberg's Arch. Pharmacol. 353 1996 200 206
53. M. Ouagued, C.A. Martin-Chouly, G. Brinchault, C. Leportier-Comoy, A. Depince, C. Bertrand, V. Lagente, C. Belleguic, and M.P. Pruniaux The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients Pulm. Pharmacol. Ther. 18 2005 49 54
54. Pitts, W. J., Watson, A. J., Dodd, J. H., and Bristol Myers Squibb., 2002. Dual inhibitors of PDE7 and PDE4. World patent (WO 02088079).
55. M. Profita, G. Chiappara, F. Mirabella, R. Di Giorgi, L. Chimenti, G. Costanzo, L. Riccobono, V. Bellia, J. Bousquet, and A.M. Vignola Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD Thorax 58 2003 573 579
56. K.F. Rabe, E.D. Bateman, D. O'Donnell, S. Witte, D. Bredenbroeker, and T.D. Bethke Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial Lancet 366 2005 563 571
57. R.R. Reinhardt, E. Chin, J. Zhou, M. Taira, T. Murata, V.C. Manganiello, and C.A. Bondy Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases J. Clin. Invest. 95 1995 1528 1538
58. A. Robichaud, P.B. Stamatiou, S.L. Jin, N. Lachance, D. MacDonald, F. Laliberte, S. Liu, Z. Huang, M. Conti, and C.C. Chan Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis J. Clin. Invest. 110 2002 1045 1052
59. S.A. Robicsek, D.K. Blanchard, J.Y. Djeu, J.J. Krzanowski, A. Szentivanyi, and J.B. Polson Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes Biochem. Pharmacol. 42 1991 869 877
60. S.D. Rybalkin, I.G. Rybalkina, M. Shimizu-Albergine, X.B. Tang, and J.A. Beavo PDE5 is converted to an activated state upon cGMP binding to the GAF A domain EMBO J. 22 2003 469 478
61. M.J. Sanz, J. Cortijo, and E.J. Morcillo PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression Pharmacol. Ther. 106 2005 269 297
62. M.J. Sanz, J. Cortijo, and E.J. Morcillo PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression Pharmacol. Ther. 106 2005 269 297
63. B.K. Sastry, C. Narasimhan, N.K. Reddy, and B.S. Raju Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study J. Am. Coll. Cardiol. 43 2004 1149 1153
64. C. Schudt, H. Tenor, and A. Hatzelmann PDE isoenzymes as targets for anti-asthma drugs Eur. Respir. J. 8 1995 1179 1183
65. A. Sebkhi, J.W. Strange, S.C. Phillips, J. Wharton, and M.R. Wilkins Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension Circulation 107 2003 3230 3235
66. Y. Shakur, L.S. Holst, T.R. Landstrom, M. Movsesian, E. Degerman, and V. Manganiello Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family Prog. Nucleic Acid Res. Mol. Biol. 66 2001 241 277
67. S.J. Smith, S. Brookes-Fazakerley, L.E. Donnelly, P.J. Barnes, M.S. Barnette, and M.A. Giembycz Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells Am. J. Physiol., Lung Cell. Mol. Physiol. 284 2003 L279 L289
68. + T-lymphocytes Mol. Pharmacol. 66 2004 1679 1689
69. J.E. Souness, M. Griffin, C. Maslen, K. Ebsworth, L.C. Scott, K. Pollock, M.N. Palfreyman, and J.A. Karlsson Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer Br. J. Pharmacol. 118 1996 649 658
70. G. Sturton, and M. Fitzgerald Phosphodiesterase 4 inhibitors for the treatment of COPD Chest 121 2002 192S 196S
71. W. Timmer, V. Leclerc, G. Birraux, M. Neuhauser, A. Hatzelmann, T. Bethke, and W. Wurst The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo J. Clin. Pharmacol. 42 2002 297 303
72. T.J. Torphy Phosphodiesterase isozymes: molecular targets for novel antiasthma agents Am. J. Respir. Crit. Care Med. 157 1998 351 370
73. T.J. Torphy, B.J. Undem, L.B. Cieslinski, M.A. Luttmann, M.L. Reeves, and D.W.P. Hay Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle J. Pharmacol. Exp. Ther. 265 1993 1213
74. T.J. Toward, and K.J. Broadley Chronic lipopolysaccharide exposure on airway function, cell infiltration, and nitric oxide generation in conscious guinea pigs: effect of rolipram and dexamethasone J. Pharmacol. Exp. Ther. 298 2001 298 306
75. T.J. Toward, N. Smith, and K.J. Broadley Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease Am. J. Respir. Crit. Care Med. 169 2004 227 234
76. D. Ukena, K. Rentz, C. Reiber, and G.W. Sybrecht Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction Respir. Med. 89 1995 441 444
77. E.M. van Schalkwyk, K. van Heerden, and D. Bredenbroker Dose-dependent inhibitory effect of roflumilast, new orally active, selective phosphodiesterase 4 inhibitor on allergen-induced early and late asthmatic reactions Eur. Respir. J. 20 Suppl 38 2002 1105
78. J. Wharton, J.W. Strange, G.M. Moller, E.J. Growcott, X. Ren, A.P. Franklyn, S.C. Phillips, and M.R. Wilkins Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells Am. J. Respir. Crit. Care Med. 172 2005 105 113
79. N. Yanaka, J. Kotera, A. Ohtsuka, H. Akatsuka, Y. Imai, H. Michibata, K. Fujishige, E. Kawai, S. Takebayashi, K. Okumura, and K. Omori Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene Eur. J. Biochem. 255 1998 391 399
80. G. Yang, K.W. McIntyre, R.M. Townsend, H.H. Shen, W.J. Pitts, J.H. Dodd, S.G. Nadler, M. McKinnon, and A.J. Watson Phosphodiesterase 7A-deficient mice have functional T cells J. Immunol. 171 2003 6414 6420
81. L. Zhao, N.A. Mason, N.W. Morrell, B. Kojonazarov, A. Sadykov, A. Maripov, M.M. Mirrakhimov, A. Aldashev, and M.R. Wilkins Sildenafil inhibits hypoxia-induced pulmonary hypertension Circulation 104 2001 424 428